Insulin therapy for type 2 diabetes.
Open accessThe DOI matches its Crossref record; 64 of the 66 references it cites were found in a registry or an index.
Abstract
A number of landmark randomized clinical trials established that insulin therapy reduces microvascular complications (1,2). In addition, recent follow-up data from the U.K. Prospective Diabetes Study (UKPDS) suggest that early insulin treatment also lowers macrovascular risk in type 2 diabetes (3). Whereas there is consensus on the need for insulin, controversy exists on how to initiate and intensify insulin therapy. The options for the practical implementation of insulin therapy are many. In this presentation, we will give an overview of the evidence on the various insulin regimens commonly used to treat type 2 diabetes. Secondary analyses of the aforementioned landmark trials endeavored to establish a glycemic threshold value below which no complications would occur. The UKPDS found no evidence for such a threshold for A1C, but instead showed that better glycemic control was associated with reduced risks of complications over the whole glycemic range (“the lower the better”) (4). For the management of type 2 diabetes, this resulted in the recommendation to “maintain glycemic levels as close to the nondiabetic range as possible” (5). However, in contrast to the UKPDS, the Kumamoto study observed a threshold, with no exacerbation of microvascular complications in patients with type 2 diabetes whose A1C was <6.5%, suggesting no additional benefit in lowering A1C below this level (2). Moreover, the intensive glycemia treatment arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, targeting A1C <6.0%, was discontinued because of higher mortality in this group compared with the standard therapy group targeting A1C from 7.0 to 7.9% (6). Therefore, the American Diabetes Association (ADA) recommendation of an A1C target <7.0% seems the most balanced compromise at present (7). Another important conclusion of the UKPDS was that the risk reductions in long-term complications were related to the levels of glycemic control …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Relationships between mean end point daily insulin dose (A) and the frequency of patient contact (clinical visits and telephone contacts combined) (B) and mean reduction in A1C, and between mean end point daily insulin dose and mean weight gain (C), during nine randomized trials investigating insulin initiation with NPH insulin, insulin detemir, or insulin glargine. Included studies are Bretzel et al. (34), Fritsche et al. (35), Hermansen et al. (28), Holman et al. (32), Philis-Tsimikas et al. (33), Riddle et al. (27), Rosenstock et al. (29), Yki-Järvinen et al. (36), and Yki-Järvinen et al. (37) (A and C). B does not include Holman, since this publication did not specify the number of interim telephone contacts. Two trials (28,35) did not report mean end point daily insulin dose as units per kilogram per day. We calculated the desired figures from the mean end point dose reported as units per day and mean body weight at study end. Three studies (Riddle and the two studies of Yki-Järvinen [27,36,37]) did not report reduction in A1C. We calculated these values from mean baseline and end point A1C levels.](https://figures.cochat.ai/paper-figures/1e9a45de404c4ea4814181c7adb4b0e3/insulin-therapy-for-type-2-diabetes-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although increasing the basal insulin dose often improves glycemic control, it can also be associated with increased risk of hypoglycemia and weight gain, resulting in inadequate intensification of insulin dose in clinical practice.1”
From Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (2022) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479 · cited 3×
“Included studies are Bretzel et al. (34), Fritsche et al. (35), Hermansen et al. (28), Holman et al. (32), Philis-Tsimikas et al. (33), Riddle et al. (27), Rosenstock et al. (29), Yki-Järvinen et al. (36), and Yki-Järvinen et al. (37) (A and C).”
Cited by
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
“Although increasing the basal insulin dose often improves glycemic control, it can also be associatedwith increased risk of hypoglycemia andweight gain, resulting in inadequate intensification of insulin dose in clinical practice.(1) When added to basal insulin, selective glucagon-like peptide-1 (GLP-1) receptor agoni…”
BackgroundSemaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
Nicholls, S. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2023.09.007 · Cited by 248
Type 2 Diabetes: The Pathologic Basis of Reversible β-Cell Dysfunction
White, M. G., Shaw, J. A. M., & Taylor, R. (2016) · Diabetes Care · doi:10.2337/dc16-0619 · Cited by 174
GhavamiNejad, A., Li, J., Lu, B., Zhou, L., Lam, L., Giacca, A., & Wu, X. Y. (2019) · Advanced Materials · doi:10.1002/adma.201901051 · Cited by 162
Pharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Lankatillake, C., Huynh, T. T., & Dias, D. A. (2019) · Plant Methods · doi:10.1186/s13007-019-0487-8 · Cited by 187
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
Swinnen, S. G., Simon, A. C., Holleman, F., Hoekstra, J. B., & DeVries, J. H. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006383.pub2 · Cited by 137
Self-citationRosenstock, J., Lorber, D. L., Gnudi, L., Howard, C. P., Bilheimer, D. W., Chang, P.-C., Petrucci, R., Boss, A., & Richardson, P. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60632-0 · Cited by 122
Cost-related medication non-adherence among U.S. adults with diabetes
Kang, H., Lobo, J. M., Kim, S., & Sohn, M.-W. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.016 · Cited by 119
“Medication regimens involving insulin may be complex because of injectable administration, variable dosing, and potentially fatal side effects such as hypoglycemia [22,23].”
BackgroundBergenstal, R. M., Rosenstock, J., Arakaki, R. F., Prince, M. J., Qu, Y., Sinha, V. P., Howey, D. C., & Jacober, S. J. (2012) · Diabetes Care · doi:10.2337/dc12-0060 · Cited by 115
Onishi, Y., Iwamoto, Y., Yoo, S. J., Clauson, P., Tamer, S. C., & Park, S. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12102 · Cited by 102
Antidiabetic Potential of Monoterpenes: A Case of Small Molecules Punching above Their Weight
Habtemariam, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010004 · Cited by 110
Mata‐Cases, M., Franch‐Nadal, J., Real, J., & Mauricio, D. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012463 · Cited by 99
Buse, J. B., Rodbard, H. W., Trescoli Serrano, C., Luo, J., Ivanyi, T., Bue-Valleskey, J., Hartman, M. L., Carey, M. A., & Chang, A. M. (2016) · Diabetes Care · doi:10.2337/dc15-1531 · Cited by 82
Factors Affecting Use of Insulin Pens by Patients With Type 2 Diabetes
Rubin, R. R., & Peyrot, M. F. (2008) · Diabetes Care · doi:10.2337/dc07-1899 · Cited by 72
Sinha, V. P., Howey, D. C., Choi, S. L., Mace, K. F., & Heise, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12222 · Cited by 61
Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1
Hager, M. V., Clydesdale, L., Gellman, S. H., Sexton, P. M., & Wootten, D. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.03.018 · Cited by 59
Bercea, M., & Lupu, A. (2024) · Gels · doi:10.3390/gels10040260 · Cited by 65
Yang, W., Ma, J., Li, Y., Li, Y., Zhou, Z., Kim, J. H., Zhao, J., & Ptaszynska, A. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12634 · Cited by 58
Kang, Y. M., Kim, Y.-J., Park, J.-Y., Lee, W. J., & Jung, C. H. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0451-0 · Cited by 53
Gandhi, G. R., Hillary, V. E., Antony, P. J., Zhong, L. L. D., Yogesh, D., Krishnakumar, N. M., Ceasar, S. A., & Gan, R. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2170320 · Cited by 60
Inhaled Insulin Forms Toxic Pulmonary Amyloid Aggregates
Lasagna‐Reeves, C. A., Clos, A. L., Midoro‐Horiuti, T., Goldblum, R. M., Jackson, G. R., & Kayed, R. (2010) · Endocrinology · doi:10.1210/en.2010-0457 · Cited by 48
Sinha, V. P., Choi, S. L., Soon, D., Mace, K. F., Yeo, K. P., Lim, S., & Howey, D. C. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.276 · Cited by 54
Rodbard, H. W., Cariou, B., Pieber, T. R., Endahl, L. A., Zacho, J., & Cooper, J. G. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12609 · Cited by 49
Tan, K. X., Danquah, M. K., Jeevanandam, J., & Barhoum, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020423 · Cited by 51
Tittel, S. R., Sondern, K., Weyer, M., Poeplau, T., Sauer, B., Schebek, M., Ludwig, K.-H., Hammer, F., Fröhlich-Reiterer, E. E., Holl, R. W., et al. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01538-0 · Cited by 44
Kaminari, A., Tsilibary, E. C., & Tzinia, A. K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180035 · Cited by 42
Heald, A. H., Livingston, M. A., Malipatil, N. S., Becher, M., Craig, J., Stedman, M., & Fryer, A. A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13067 · Cited by 35
Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Aiysha Thompson, K. (2013) · Clinical & Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 33
Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan
Al-Maatouq, M. A. (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s23261 · Cited by 36
Mikiewicz, D., Bierczyńska-Krzysik, A., Sobolewska, A., Stadnik, D., Bogiel, M., Pawłowska, M., Wójtowicz-Krawiec, A., Baran, P., Łukasiewicz, N., Romanik-Chruścielewska, A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172600 · Cited by 35
Blevins, T., Barve, A. J., Sun, B., Raiter, Y., Aubonnet, P., Muniz, R., Athalye, S. N., & Ankersen, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13495 · Cited by 31
“Conventional basal NPH insulin has pharmacodynamic limitations that predispose users to elevated glucose levels before breakfast as well as to nocturnal hypoglycaemia.(4) To overcome these challenges, basal insulin analogues (eg, insulin glargine 100 or 300 U/mL or detemir)(5) with modified amino acid sequences from h…”
BackgroundGoyal, A., Gupta, Y., & Tandon, N. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01210-6 · Cited by 43
Type 2 Diabetes Mellitus and Asthma: Pathomechanisms of Their Association and Clinical Implications
Uppal, P., Mohammed, S. A., Rajashekar, S., Ravindran, S. G., Kakarla, M., Gambo, M. A., Salama, M. Y., Ismail, N. H., Tavalla, P., & Hamid, P. (2023) · Cureus · doi:10.7759/cureus.36047 · Cited by 39
“Insulin therapy is employed in T2DM when oral antidiabetic drugs fail to adequately control blood glucose levels after multiple glucose-lowering agents have been initiated in a step-wise manner during the progressive course of the disease [49].”
BackgroundAtomic resolution structure of full-length human insulin fibrils
Suladze, S., Sarkar, R., Rodina, N. P., Bokvist, K. B., Krewinkel, M., Scheps, D., Nagel, N., Bardiaux, B., & Reif, B. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2401458121 · Cited by 30
Rašlová, K. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s10397 · Cited by 38
Multi-organ denervation: a novel approach to combat cardiometabolic disease
Kiuchi, M. G., Carnagarin, R., Matthews, V. B., & Schlaich, M. P. (2023) · Hypertension Research · doi:10.1038/s41440-023-01287-x · Cited by 27
König, M., & Holzhütter, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.382069 · Cited by 27
Fu, S. N., Chin, W. Y., Wong, C. K. H., Yeung, V. T. F., Yiu, M. P., Tsui, H., & Chan, K. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078933 · Cited by 29
Ho, Y.-J., Chen, W., Chi, T.-C., Chien, C.-C. C., Lee, A., Chiu, H., Kuo, Y., & Su, M. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-99 · Cited by 25
Mauricio, D., & HRAMIAK, I. M. (2018) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2018.14supp1.2 · Cited by 25
The closed‐loop artificial pancreas in 2020
Fabris, C., & Kovatchev, B. P. (2020) · Artificial Organs · doi:10.1111/aor.13704 · Cited by 24
Özkan, U., & Gürdoğan, M. (2023) · Medicina · doi:10.3390/medicina59030505 · Cited by 29
Aras, E., Ramadori, G., Kinouchi, K., Liu, Y., Ioris, R. M., Brénachot, X., Ljubicic, S., Veyrat‐Durebex, C., Mannucci, S., Galiè, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.093 · Cited by 23
Mayet, L., & Naidoo, S. (2012) · South African Family Practice · doi:10.1080/20786204.2012.10874287 · Cited by 19
Abdul-Ghani, M., Williams, K., Kanat, M., Altuntaş, Y., & DeFronzo, R. (2013) · Journal of Endocrinological Investigation · doi:10.3275/8367 · Cited by 22
Bockwoldt, D., Staffileno, B. A., Coke, L. A., Hamilton, R., Fogg, L., Calvin, D. J., & Quinn, L. (2016) · Journal of Transcultural Nursing · doi:10.1177/1043659616651674 · Cited by 20
Oh, T. K., & Song, I. (2020) · Bone · doi:10.1016/j.bone.2020.115325 · Cited by 19
Jones, A. G., Besser, R. E. J., Shields, B. M., McDonald, T. J., Hope, S. V., Knight, B., & Hattersley, A. T. (2012) · BMC Endocrine Disorders · doi:10.1186/1472-6823-12-6 · Cited by 20
Liu, J. W., Ahn, J., Nakonezny, P. A., Lalli, T. A. J., VanPelt, M. D., Raspovic, K. M., Wukich, D. K., & Liu, G. T. (2021) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2021.03.011 · Cited by 21
Chadha, M. D., Jain, S. M., Chawla, R., Dharmalingam, M., Chaudhury, T., Talwalkar, P., Tripathi, S., Singh, S., Gutch, M., & Dasgupta, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230116150205 · Cited by 20
Park, M.-S., Zhu, Y. X., Pae, H., & Park, S. H. (2016) · Journal of Food Biochemistry · doi:10.1111/jfbc.12252 · Cited by 21
Emad-Eldin, M., Balata, G. F., el-Shorbagy, E., Hamed, M. S., & Attia, M. S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.828 · Cited by 31
Kotiso, K. S., Degemu, N., Gebremedhin, S., Taye, M., Petros, A., Belayneh, F., Wolde, D., & Hailu, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256399 · Cited by 17
“Though this interaction needs further investigation, it may be partly explained by the fact that type 2 diabetic patients who were on insulin might have experienced poor glycemic control probably due to insulin resistance [41].”
BackgroundChien, M.-N., Chen, Y., Hung, Y., Wang, S., Lu, W.-T., Chen, C., Lin, C., Huang, T., Tsai, M., Tseng, W., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12532 · Cited by 15
Garodia, N., KUMAR, K. M. P., Ghosh, S., Canovatchel, W. J., & Rajashekar, S. T. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.196016 · Cited by 19
Jabbour, S. A., Whaley, J. M., Tirmenstein, M. A., Poucher, S. M., Reilly, T. P., Boulton, D. W., Saye, J. A., List, J. F., & Parikh, S. J. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2569 · Cited by 16
Call-to-action: Timely and appropriate treatment for people with type 2 diabetes in Latin America
Escalante, M., Gagliardino, J. J., Guzmán, J. R., & Tschiedel, B. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.004 · Cited by 21
Jeevanandam, J., Chan, Y. S., Danquah, M. K., & Law, M. C. (2019) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-019-03166-z · Cited by 16
Otieno, F. C. F., Mikhail, T., Acharya, K., Muga, J., Ngugi, N., & Njenga, E. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100093 · Cited by 16
Liu, J., & Hu, X. (2022) · Diabetes and Vascular Disease Research · doi:10.1177/14791641221093175 · Cited by 15
Exploiting common aspects of obesity and cancer cachexia for future therapeutic strategies
Molocea, C., Tsokanos, F., & Herzig, S. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.07.006 · Cited by 15
Khan, N. M., Ahmad, A., Tiwari, R., Kamal, M. A., Mushtaq, G., & Ashraf, G. M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141023160448 · Cited by 20
Joshi, S., Jayanth, V., Loganathan, S., Sambandamurthy, V. K., & Athalye, S. N. (2023) · Drugs · doi:10.1007/s40265-023-01925-1 · Cited by 16
Prevalence of Diabetic Retinopathy among Type - 2 Diabetes Patients in Pakistan - Vision Registry
Sohail, M. R. (2014) · Pakistan Journal of Ophthalmology · doi:10.36351/pjo.v30i4.201 · Cited by 26
Advances in Nanomedicine Design: Multidisciplinary Strategies for Unmet Medical Needs
Ahmed, T., Liu, F.-C. F., Lu, B., Lip, H., Park, E., Alradwan, I. A., Liu, J. F., He, C., Zetrini, A., Zhang, T., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00038 · Cited by 15
Barriers and facilitators to insulin treatment: a phenomenological inquiry
Bayked, E. M., Kahissay, M. H., & Workneh, B. D. (2022) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-022-00441-z · Cited by 20
Park, D., Barka, G. D., Yang, E.-Y., Cho, M.-C., Yoon, J. B., & Lee, J. (2020) · Genes · doi:10.3390/genes11101116 · Cited by 14
Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery
Pradyuth, K. S., Kumar, A., Chitkara, D., & Mittal, A. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001679 · Cited by 17
Ozawa, F., Nagata, S., Oda, H., Yabe, S. G., Okochi, H., & Takeuchi, S. (2021) · iScience · doi:10.1016/j.isci.2021.102309 · Cited by 16
Initiation of insulin among veterans with type 2 diabetes and sustained elevation of A1c
Parchman, M. L., & Wang, C.-P. (2011) · Primary care diabetes · doi:10.1016/j.pcd.2011.06.006 · Cited by 13
Yu, T. S., Song, S., Yea, J., & Jang, K. (2024) · Advanced Sensor Research · doi:10.1002/adsr.202400048 · Cited by 16
Mechanisms of Diabetic Nephropathy Not Mediated by Hyperglycemia
Viggiano, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216848 · Cited by 14
Pradhan, R., Yin, H., Yu, O. H. Y., & Azoulay, L. (2019) · Drug Safety · doi:10.1007/s40264-019-00892-5 · Cited by 12
Herold, Z., Herold, M., Rosta, K., Doleschall, M., & Somogyi, A. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00569-5 · Cited by 12
Tuccinardi, D., Giorgino, R., Pieralice, S., Watanabe, M., Maggi, D., Palermo, A., Defeudis, G., Fioriti, E., Pozzilli, P., & Manfrini, S. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01634-1 · Cited by 13
Sonthon, P., Promthet, S. S., Changsirikulchai, S., Rangsin, R., Thinkhamrop, B., Rattanamongkolgul, S., & Hurst, C. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180977 · Cited by 18
Berardet, C., Kaffy, J., Ongeri, S., & Taverna, M. (2018) · Journal of Chromatography A · doi:10.1016/j.chroma.2018.10.006 · Cited by 11
Carnagarin, R., Kiuchi, M. G., Goh, G. S., Adams, L. A., Cohen, N. D., Kavnoudias, H., Gan, S. K., van Schie, G., Esler, M., Matthews, V. B., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002839 · Cited by 11
“These complex therapeutic regimens have been associated with a higher risk of hypoglycemia [95] with reported incidence rates of up to 36.”
BackgroundNurse-led diabetes clinics in Southeast Asia: scope, feasibility, challenges and facilitators
K Sharma, S., Thakur, K., Kant, R., & Kalra, S. (2020) · Journal of Diabetes, Metabolic Disorders & Control · doi:10.15406/jdmdc.2020.07.00199 · Cited by 8
Wada, E., Onoue, T., Kinoshita, T., Hayase, A., Handa, T., Ito, M., Furukawa, M., Okuji, T., Kobayashi, T., Iwama, S., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05516-1 · Cited by 13
Petakh, P., Kamyshna, I. I., & Kamyshnyi, O. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01341-7 · Cited by 11
Baker, D. J., Atkinson, A. M., Wilkinson, G., Coope, G., Charles, A., & Leighton, B. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12498 · Cited by 14
“The doses of insulin used in this study (1 unit·kg−1) are slightly higher than the typical dose range for man (∼0.2–0.8 units·kg−1; Swinnen et al., 2009) to adjust for the differences in pharmacodynamic profile in rodents.”
MethodInfluentialAmutha, A., Praveen, P. A., Hockett, C. W., Ong, T. C., Jensen, E. T., Isom, S. P., D'Agostino, R. B. J., Hamman, R. F., Mayer‐Davis, E. J., Wadwa, R. P., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13004 · Cited by 12
Uehara, R., Yamada, E., Nakajima, Y., Osaki, A., Okada, S., & Yamada, M. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13257 · Cited by 10
Feng, Z., Tong, W. K., Zhang, X., & Tang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1226778 · Cited by 13
Sheu, W. H., Park, S. W., Gong, Y., Pinnetti, S., Bhattacharya, S., Patel, S. D., Seck, T. L., & Woerle, H. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1010638 · Cited by 10
Megson, I. L., Treweeke, A. T., Shaw, A., MacRury, S. M., Setford, S. J., Frías, J. P., & Anhalt, H. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815570359 · Cited by 10
Development, optimization, and biovalidation of 99mTc–insulin complex
Akbar, M. U., Bokhari, T. H., Roohi, S., Zia, K. M., Zuber, M., Parveen, N., & Ali, N. (2016) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162016050125 · Cited by 10
Pawaskar, M. D., Bilir, S. P., KOWAL, S. L., González, C. D., Rajpathak, S. N., & Davies, G. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13618 · Cited by 11
“NPH insulin is frequently used in this subsequent intensification step because of its combination of effectiveness and relatively low cost.(10) However, safety considerations associated with insulin therapy, such as increases in hypoglycaemia and weight gain, and the complexity of using inject-”
BackgroundPrato, S. D., Frías, J. P., Blonde, L., Aroda, V. R., Shehadeh, N., Saremi, A., DEX, T. A., Niemoeller, E., Souhami, E., Liu, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14068 · Cited by 10
Improving the stability of insulin through effective chemical modifications: A Comprehensive review
Kamelnia, R., Ahmadi‐hamedani, M., Darroudi, M., & Kamelnia, E. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124399 · Cited by 9
Hamza, S. M., Sung, M. M. Y., Gao, F., Soltys, C.-L. M., Smith, N. P., MacDonald, P. E., Light, P. E., & Dyck, J. R. B. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.11.029 · Cited by 10
Perceptions of Insulin Treatment Among African Americans With Uncontrolled Type 2 Diabetes
Bockwoldt, D., Staffileno, B. A., Coke, L. A., & Quinn, L. T. (2014) · Journal of Transcultural Nursing · doi:10.1177/1043659614543477 · Cited by 13
Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
Heyns, I. M., Davis, G., Ganugula, R., Kumar, M. N. V. R., & Arora, M. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00839-w · Cited by 11
Influence of Ageism on Physical Activity Prescription for Prediabetes Management
Eswaran, A., & Meisner, B. A. (2021) · Journal of Aging and Physical Activity · doi:10.1123/japa.2021-0199 · Cited by 13
Suthar, A. C., Pai, V., Kadam, Y., Tongaonkar, A., Kale, S. C., Deshpande, A. B., Kolke, S., Tanna, S., Deshpande, S. V., CHAWLA, P. M., et al. (2016) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2016.61005 · Cited by 9
Metadata
- Authors
- Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Swinnen, Sanne G.
- ORCID
- DeVries, J. Hans
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-11-01
- Volume
- 32
- Issue
- suppl_2
- Pages
- S253-S259
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2811456
- OpenAlex
- W2131037080
- Semantic Scholar
- a5b8f30bf6ffc652e3e70e51ae28659874032190
- Cited by
- 181
- References
- 66
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 15 · 2023: 21 · 2022: 19 · 2021: 12 · 2020: 14 · 2019: 7 · 2018: 8 · 2017: 10 · 2016: 11 · 2015: 7 · 2014: 11 · 2013: 10 · 2012: 10
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Sanofi
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin therapy, type 2 diabetes, insulin regimens, glycemic control, HbA1c targets, microvascular complications, UKPDS, ACCORD trial, tight glycemic control
- MeSH terms
- Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Insulin, Quality of Life, Patient Satisfaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.